|Articles|September 3, 2019

An Estimated 5700 Zika Cases Went Unreported in 2017 Cuban Outbreak

Author(s)Einav Keet

Although Cuba reported no cases of Zika virus in 2017 and 2018, investigators used travel data and genomic epidemiology to uncover a large, “hidden” Zika outbreak.

Using travel data and genomic sequencing, investigators have discovered that an unreported Zika virus outbreak occurred in Cuba in 2017.

Although Zika virus was first identified decades ago in the Zika Forest of Uganda, the virus was relatively unknown before 2015 when a very public outbreak sparked in Brazil. Following additional outbreaks in other South American, Central American, and Caribbean countries along with associated cases of microcephaly in infants, the World Health Organization (WHO) declared a Public Health Emergency of International Concern in February 2016. Although the case counts waned over that year, a new report published in the journal Cell says that a large outbreak of Zika virus was just beginning in Cuba, one which went unreported until investigators began to connect the dots.

Mosquito exposure and lack of access to adequate health care can result in undetected cases of Zika virus and other illnesses, the investigators reported. “Pockets of virus transmission that occur in countries with inadequate reporting can therefore facilitate ‘hidden’ outbreaks, increasing the risk of infected travelers causing outbreaks in new regions of the world,” the authors wrote. “Thus, underreported or unrecognized local outbreaks may prolong epidemics and hinder global efforts aimed at halting virus spread.”

The study team hypothesized that Zika outbreaks could still be occurring in the Americas without being detected by public health agencies. To find locations with continuing and unreported Zika virus outbreaks, the investigators used data on international travel-associated Zika cases from the Florida Department of Health and the European Centre for Disease Prevention and Control (ECDC) to examine to identify transmission not captured by reporting. In addition, the study team used clinical sequencing of Zika virus from infected travelers.

They discovered that in 2017 there was a spike in Zika cases in travelers who had been to the Caribbean, and found that between June 2017 and October 2018, 98% of travel-associated Zika cases reported in Florida and Europe came from Cuba. In addition, the investigators found that 76% of the Zika cases associated with travel from Cuba were diagnosed in 2017. Although Cuba reported 187 laboratory-confirmed Zika cases in 2016, it reported no local Zika cases to the Pan American Health Organization or other international public health agencies in 2017 and 2018.

In an interview with Contagion®, Scott F. Michael, PhD, professor of biological sciences at Florida Gulf Coast University, and an author on the study, explained how his team’s work highlights the ways Zika virus may still be silently spreading. “One of the most important aspects of our study is that by using a combination of molecular epidemiology and travel information, we can reconstruct outbreaks without local reporting, regardless of the reason,” he said. “Using a similar approach, unreported disease outbreaks could be monitored from any location with significant travel. As travel is the major route of outbreak spread, this approach might be useful in many situations.”

By creating a model based on existing data on the relationship between local and travel-associated Zika infection rates, the study team determined that the Cuba outbreak likely had 5707 unreported Zika cases, comparable to large outbreaks in other Caribbean countries. More than 99% of those cases occurred in 2017, although the study team called it unusual that the Cuban outbreak had a 1-year delay compared with other Caribbean outbreaks. “Although we don’t have direct data, we speculate that mosquito control efforts may have had enough impact to hold off establishment of local transmission for a year,” Michael said.

As Zika outbreaks continue to occur in countries such as Angola, India, Cabo Verde, Vietnam, and Thailand, the study team says their findings shed light on the importance of case reporting and could be used to detect additional “hidden” outbreaks.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.